Search Within

Karthik Nath

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Meeting Abstract (8)
  2. Journal Article (4)
  3. Correspondence (1)
Groups
  1. Biostatistics Service (13)
  2. Bone Marrow Transplant (13)
  3. CTCR Scholars (13)
  4. Center for Hematologic Malignancies (13)
  5. Department of Medicine (13)
  6. Epidemiology and Biostatistics (13)

More Groups

People
  1. Gunjan Shah (13)
  2. Sergio Giralt (13)
  3. Michael Scordo (12)
  4. Alexander Lesokhin (10)
  5. Carlyn Rose Tan (10)
  6. Hani Hassoun (10)

More People

Years
  1. 2024 (4)
  2. 2023 (5)
  3. 2022 (4)
Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (4)
  2. Blood (3)
  3. Blood Cancer Journal (2)
  4. Transplantation and Cellular Therapy (2)
  5. Leukemia and Lymphoma (1)
  6. New England Journal of Medicine (1)
Publishers
  1. Elsevier Inc. (6)
  2. American Society of Hematology (3)
  3. Nature Publishing Group (2)
  4. Massachusetts Medical Society (1)
  5. Taylor & Francis Group (1)

Results (13)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Infectious complications during treatment with commercial CAR T-cell therapy and bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E. M.; Shekarkhand, T.; Farzana, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R. S.; Nishimura, N.; Miller, K.; Costa, B. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Incidence and clinical impact of acute kidney injury: A comparison of CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B.; Farzana, T.; Jurgens, E.; Firestone, R.; Nath, K.; Chung, D.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
    Journal Article

    Nath, K.; Shekarkhand, T.; Nemirovsky, D.; Derkach, A.; Costa, B. A.; Nishimura, N.; Farzana, T.; Rueda, C.; Chung, D. J.; Landau, H. J.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma
    Journal Article

    Costa, B. A.; Flynn, J.; Nishimura, N.; Devlin, S. M.; Farzana, T.; Rajeeve, S.; Chung, D. J.; Landau, H. J.; Lahoud, O. B.; Scordo, M.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Comparison of bendamustine versus fludarabine/cyclophosphamide lymphodepletion in adult patients receiving CD19 CAR-T cell therapy
    Meeting Abstract

    Landego, I.; Nemirovsky, D.; Devlin, S. M.; Wills, B.; Parascondola, A.; Saldia, A.; Dahi, P. B.; Tomas, A. A.; Ip, A.; Suh, H. C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A comparative analysis of infectious complications in patients with multiple myeloma treated with BCMA-targeted bispecific antibodies and CAR T-cell therapy
    Meeting Abstract

    Nath, K.; Shekarkhand, T.; Costa, B. A.; Nemirovsky, D.; Derkach, A.; Nishimura, N.; Farzana, T.; Rueda, C.; Chung, D.; Landau, H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Nath, K.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Vitamin D deficiency and clinical outcomes with chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Prognostic impact of corticosteroid and tocilizumab use on the efficacy of chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Flynn, J.; Nath, K.; Nishimura, N.; Devlin, S.; Farzana, T.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
    Correspondence

    Nath, K.; Shekarkhand, T.; Salcedo, M.; Derkach, A.; Rueda, S.; Chansakul, A.; Hulcrantz, M.; Korde, N.; Shah, U. A.; Tan, C.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save